A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Selected Articles from This Issue
2021
Molecular Cancer Therapeutics
Cytidine analogs remain an area of active drug discovery and development with five FDA-approved drugs. Herein F-aza-T-dCyd (NSC801845), a novel fluorine-containing cytidine analog, is first disclosed and compared in cell culture and human tumor xenograft studies with gemcitabine and several investigational cytidine agents currently undergoing clinical development. In the 3 of 5 xenograft studies (HCT-116 colon, HL-60 leukemia, PDX BL-0382 bladder), F-aza-T-dCyd produced complete regression of
doi:10.1158/1535-7163.623.20.4
fatcat:s23ycnth5nfnrdgi2nkzytjhrm